{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T15:32:04Z","timestamp":1757777524222,"version":"3.37.3"},"reference-count":8,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,2]]},"DOI":"10.1182\/blood.2022015963","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T15:33:52Z","timestamp":1654184032000},"page":"3229-3230","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["A CAPTIVATE-ing new regimen for CLL"],"prefix":"10.1182","volume":"139","author":[{"given":"Kerry A.","family":"Rogers","sequence":"first","affiliation":[{"name":"The Ohio State University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-9144","authenticated-orcid":false,"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"The Ohio State University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"22","key":"2022060215334278200_B1","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood."},{"issue":"31","key":"2022060215334278200_B2","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1200\/JCO.20.00491","article-title":"Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-na\u00efve and relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Rogers","year":"2020","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022060215334278200_B3","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol."},{"issue":"36","key":"2022060215334278200_B4","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1200\/JCO.21.01181","article-title":"Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study","volume":"39","author":"Al-Sawaf","year":"2021","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022060215334278200_B5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia."},{"journal-title":"Leukemia.","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia [published online ahead of print 1 January 2022]","author":"Sharman","key":"2022060215334278200_B6"},{"key":"2022060215334278200_B7","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-151471","article-title":"A041702: a randomized phase III study of ibrutinib plus obinutuzumab vs ibrutinib plus venetoclax and obinutuzumab in untreated older patients (\u226570 years of age) with chronic lymphocytic leukemia (CLL) [abstract]","volume":"138","author":"Woyach","year":"2021","journal-title":"Blood."},{"issue":"22","key":"2022060215334278200_B8","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/22\/3229\/1900271\/bloodbld2022015963c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/22\/3229\/1900271\/bloodbld2022015963c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T15:34:02Z","timestamp":1654184042000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/22\/3229\/485342\/A-CAPTIVATE-ing-new-regimen-for-CLL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":8,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2022,6,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022015963","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2022,6,2]]}}}